NGeneBio Co., Ltd. Q3 revenue KRW 13.4 billion, operating loss KRW 1.3 billion
NAI summary · Not investment advice
In Q3, Engenbio sold KRW 13.4 billion worth and lost KRW 1.3 billion from its main business; sales rose 147.5% from a year earlier and 7.9% from the prior quarter.
Operating profit · 3 months
KRW -1.3 billion
Key facts
- Revenue (3 months)
- KRW 13.4 billion
- Net income (3 months)
- KRW -3.5 billion
- Period
- Q3 (cumulative Jan 1, 2026 ~ Sep 30, 2026)
- Revenue (prior-year 3 months)
- KRW 5.4 billion
- Revenue (year to date)
- KRW 37.8 billion
- Operating profit (prior-year 3 months)
- KRW -1.6 billion
- Operating profit (year to date)
- KRW -4.1 billion
- Net income (prior-year 3 months)
- KRW -1.9 billion
- Net income (year to date)
- KRW -11.1 billion
Commentary
AI commentary · Not investment advice
What happened
Engene Bio reported its consolidated results for the third quarter of 2026. Sales for the latest 3 months were KRW 13.44 billion. That is 147.5% more than the same 3 months a year earlier (KRW 5.43 billion). It is also 7.9% more than the previous quarter.
In the company's terms
Operating profit (profit from the main business) for the 3 months was a loss of KRW 1.31 billion. A year earlier it was a loss of KRW 1.65 billion. Net income (final profit after taxes and all other items) for the 3 months was a loss of KRW 3.48 billion. A year earlier it was a loss of KRW 1.94 billion.
What changes for shareholders
For the year to date, sales were KRW 37.84 billion. Operating profit was a loss of KRW 4.06 billion. Net income was a loss of KRW 11.12 billion.
Comments
No comments yet
Comments from shareholders will appear here.
Get the next disclosure as an app alert
Get app alerts for new disclosures and stake changes on your watchlist